Catalysis research strengthened: Helmholtz-Zentrum Berlin participates in newly approved Einstein Center for Catalysis
HZB scientists develop new methods to investigate the electronic structure of catalytic molecules.
© HZB
The Einstein Foundation will fund the new Einstein Center for Catalysis (EC2) beginning in 2016 in which Technical University Berlin (TU Berlin) and selected non-university institutions in Berlin will be participating. Prof. Emad Aziz, head of the HZB Institute for Methods of Materials Research at Helmholtz-Zentrum Berlin will be taking part in setting up the institution. His team will be contributing particular expertise in analytics of ultrafast processes in catalytic reactions.
Catalysis is a key topic of the future, whether for the energy transition or for processing of raw materials. If we want to utilise resources more efficiently and sustainably in the future, outstanding catalysts are indispensable. HZB is therefore strengthening its catalysis research and working with collaborating partners toward specific goals.
Methods will be developed at the Einstein Center for Catalysis (EC2) that facilitate deeper investigation of chemical and biological catalysts. The dynamics of catalysis processes in particular will be better understood with these methods. “The formation of the inter-institutional Einstein Center for Catalysis is a real milestone for catalysis research in Berlin. HZB will be involved even more strongly in catalysis research on Energy Materials in the future“, says Prof. Anke Kaysser-Pyzalla, Scientific Director of HZB.
The new Einstein Center builds on the UniCat (Unifying Concepts in Catalysis) Excellence Cluster at Technische Universität Berlin (TU Berlin). Besides HZB, the main partners in the new Einstein Center are the Fritz Haber Institute of the Max Planck Society, the Leibniz Institute for Molecular Pharmacology Berlin, the Leibniz Institute for Analytical Sciences Berlin, as well as the UniCat-BASF Joint Lab. The spokesperson of the new Einstein Center is Prof. Matthias Drieß from the Organometallic Chemistry and Inorganic Materials branch of the Department of Chemistry, TU Berlin. “In order to be able to determine the dynamics of active reaction centers with a high degree of temporal as well as spatial resolution, we need HZB as a partner with its outstanding analytics at BESSY II ”, says Drieß.
The HZB Institute for Methods of Material Development develops new experimental methods that utilise light in the X-ray or extreme UV regions. “These methods permit us to make new tools available in order to investigate the electronic structure of catalytic molecules and the ultrafast processes that occur during catalysis under realistic conditions like room temperature and standard atmospheric pressure”, explains Aziz. “Dr. Tristan Petit and Dr. Annika Bande, whose groups are supported by Freigeist grants from the Volkswagen Foundation, will also benefit from the large network of catalysis research in Berlin.”
The new Einstein Center is to be funded initially for five years beginning in January 2016.
- Protein crystallography at BESSY II: faster, better and more and more automaticMany diseases are linked to malfunctions of proteins in the organism. The three-dimensional architecture of these molecules is often highly complex, but it can provide valuable insights into biological processes and the development of drugs. X-ray diffraction at the MX beamlines of BESSY II can be used to decipher the 3D structure of proteins. To date, more than 5000 structures have been solved at the three MX beamlines. Here, we present a review and an outlook with Manfred Weiss, head of the research group for macromolecular crystallography.
- Humboldt-Fellow at HZB-Institute for Solar Fuels: Alexander R. UhlAlexander R. Uhl, UBC Okanagan School of Engineering in Kelowna, Canada, aims to develop with Roel van de Krol from the HZB Institute for Solar Fuels an efficient and inexpensive photoelectrolyser for producing hydrogen using sunlight. His stay is being funded by the Alexander von Humboldt Foundation.
- 5000th protein structure at BESSY II: Starting point for a COVID drugMany proteins have a complex architecture that enables biological functions. Molecules can bind to specific sites on a protein and alter its function. A team at HZB has now investigated the Nsp1 protein, which plays a role in infection with the SARS-CoV-2 virus. They analysed protein crystals, previously mixed with molecules from a fragment library, and discovered a total of 21 candidates as starting points for drug development. At the same time, they also decoded the 5000th structure at BESSY II.